Brookline Capital Management Analyst Ratings & Stock Recommendations

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from pubilc media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

DateBrokerageActionCompany
Name
RatingPrice
Target
Impact on
Share Price
Actions
2/6/2019Brookline Capital ManagementReiteratesChiasma (CHMA)BuyLowView Rating Details  Share on Twitter  Share on StockTwits
1/4/2019Brookline Capital ManagementReiteratesSCYNEXIS (SCYX)BuyHighView Rating Details  Share on Twitter  Share on StockTwits
11/27/2018Brookline Capital ManagementReiteratesRexahn Pharmaceuticals (RNN)BuyN/AView Rating Details  Share on Twitter  Share on StockTwits
11/27/2018Brookline Capital ManagementReiteratesRexahn Pharmaceuticals (RNN)BuyMediumView Rating Details  Share on Twitter  Share on StockTwits
11/20/2018Brookline Capital ManagementReiteratesCelsion (CLSN)BuyMediumView Rating Details  Share on Twitter  Share on StockTwits
11/20/2018Brookline Capital ManagementReiteratesCellectar Biosciences (CLRB)BuyLowView Rating Details  Share on Twitter  Share on StockTwits
9/27/2018Brookline Capital ManagementReiteratesArcturus Therapeutics (ARCT)BuyLowView Rating Details  Share on Twitter  Share on StockTwits
8/1/2018Brookline Capital ManagementReiteratesHeat Biologics (HTBX)BuyLowView Rating Details  Share on Twitter  Share on StockTwits
8/1/2018Brookline Capital ManagementReiteratesHistogenics (HSGX)BuyMediumView Rating Details  Share on Twitter  Share on StockTwits
7/27/2018Brookline Capital ManagementDowngradesTonix Pharmaceuticals (TNXP)Buy -> HoldLowView Rating Details  Share on Twitter  Share on StockTwits
6/26/2018Brookline Capital ManagementReiteratesProteon Therapeutics (PRTO)BuyMediumView Rating Details  Share on Twitter  Share on StockTwits
5/1/2018Brookline Capital ManagementReiteratesTonix Pharmaceuticals (TNXP)BuyLowView Rating Details  Share on Twitter  Share on StockTwits

This page was last refreshed on Friday at 04:15 PM ET.

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:  1.9 out of 5 (star half star)
Outperform Votes:  10,846 (Vote Outperform)
Underperform Votes:  17,165 (Vote Underperform)
Total Votes:  28,011
MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recmomendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel